CMTM6 drives cisplatin resistance in OSCC by regulating AKT mediated Wnt signaling
P. Mohapatra, O. Shriwas, S. Mohanty, S. R. Kaushik, R. Arya, R. Rath, S. Das Majumdar, D. Muduly, R. K. Nanda, R. Dash
Abstract
Chemoresistance is one of the important factors for treatment failure in OSCC, which can culminate in progressive tumor growth and metastatic spread. Rewiring tumor cells to undergo drug-induced apoptosis is a promising way to overcome chemoresistance, which can be achieved by identifying the causative factors for acquired chemoresistance. In this study, to explore the key cisplatin resistance triggering factors, we performed global proteomic profiling of OSCC lines representing with sensitive, early and late cisplatin-resistant patterns. The top ranked up-regulated protein appeared to be CMTM6. We found CMTM6 to be elevated in both early and late cisplatin-resistant cells with respect to the sensitive counterpart. Analyses of OSCC patient samples indicate that CMTM6 expression is upregulated in chemotherapy-non-responder tumors as compared to chemotherapy-naive tumors. Stable knockdown of CMTM6 restores cisplatin-mediated cell death in chemoresistant OSCC lines. Similarly, upon CMTM6 overexpression in CMTM6KD lines, the cisplatin resistant phenotype was efficiently rescued. Mechanistically, it was found that CMTM6 interacts with membrane bound Enolase-1 and stabilized its expression, which in turn activates the AKT-GSK3{beta} mediated Wnt signaling. CMTM6 triggers the translocation of {beta}-catenin into the nucleus, which elevates the Wnt target pro-survival genes like Cyclin D, c-Myc and CD44. Moreover, incubation with lithium chloride, a Wnt signaling activator, efficiently rescued the chemoresistant phenotype in CMTM6KD OSCC lines. In a patient-derived cell xenograft model of chemoresistant OSCC, knock-down of CMTM6 restores cisplatin induced cell death and results in significant reduction of tumor burden. CMTM6 has recently been identified as a stabilizer of PD-L1 and henceforth it facilitates immune evasion by tumor cells. Herewith for the first time, we uncovered another novel role of CMTM6 as one of the major driver of cisplatin resistance.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- CMTM6 mediates cisplatin resistance in OSCC by regulating AKT/c-MYC driven ribosome biogenesis
P. Mohapatra, S. Mohanty, … R. Dash·bioRxiv·Apr 8, 2022
- RRBP1 rewires cisplatin resistance in Oral Squamous Cell Carcinoma by regulating YAP-1
O. Shriwas, R. Arya, … R. Dash·bioRxiv·Mar 18, 2020
- Secreted soluble factors from tumor-activated mesenchymal stromal cells confer platinum chemoresistance to ovarian cancer cells
Y. Koren Carmi, R. Adawi, … J. Mahajna·bioRxiv·Feb 24, 2023
- Inhibition of miR-1307 Reverses Resistance to Cisplatin in Drug-Resistant Oral Squamous Cell Carcinoma
Aditi Patel, Vaishnavi Patel, … Shanaya Patel·bioRxiv·Apr 9, 2026
- Cisplatin-Induced Plasticity Drives Cross-Resistance to CDK4/6 Inhibitors and Reveals Targetable Vulnerabilities Through HDAC Inhibition in Esophageal Squamous Cell Carcinoma.
Marta Ávalos-Moreno, Aurora Vigato, … Xavier Bisteau·bioRxiv·Jul 17, 2026
- Modeling platinum resistance in a stem-like patient-derived ovarian cancer sample
Tise Suzuki, Ashlyn Conant, … Juli J. Unternaehrer·International Journal of Molecular SciencesPeer-reviewed·Mar 29, 2024